Ed Koval, MBA

Interim Head, Business Development

Ed Koval joined X-Rx in 2017 as a strategic consultant and more recently as Interim Head, Business Development.   Mr. Koval bring more than 20 years of strategy, business / corporate development and finance experience to the company.   Drawing on in-house and consulting insights acquired during several stints in large pharma and emerging biotechs, Ed’s experience cuts across the entire R&D and commercialization value chain as well as multiple therapeutic areas and discovery platforms.  His transactions, both from the buy and sell sides, include the entire range of corporate agreements, from licenses and collaborations to Joint Ventures, financings and M&A.  Mr. Koval started his career at Merck as a financial analysis and licensing transaction manager.  He later joined Chiron as a corporate development director and Novartis as a VP of business development and alliance management for the cardiovascular-metabolic, neuroscience and vaccine businesses.   More recently Ed was head of corporate development at Veloxis, a specialty pharmaceuticals company.  Mr. Koval holds a B.S. and M.S. degrees in engineering from NYU and RPI as well as an M.B.A from the MIT Sloan School of Management.